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INTRODUCTION
Patients infected with HIV often present with 
derangements involving the ear, which negatively 
impact on the quality of life. The actual incidence of 
ear disease and hearing loss in this patient population 
is not known and this is of particular concern because 
the disability of partial or complete hearing loss is 
magnified in a person with many other medical 
problems (1). 
 A variety of adverse effects have been attributed 
to treatment with nucleoside reverse transcriptase 
inhibitors (NRTIs) but so far only a few cases ofneuro-
ototoxicity have been reported in the literature 
(2,3). HIV infections together with opportunistic 
infections have been reported in literature to 
cause up to 50% of the hearing loss (4). Marra et 
al. showed that HIV-1 infected patients without 
significant immunosuppression developed hearing 
abnormalities during the follow-up particularly after 
exposure to anti - retroviral drugs (3, 4,). The hearing 
impairment is common with use of NRTIs, especially 
lamivudine, didanosine and stavudine and therefore 
patients on these drugs need to have close auditory 
function assessments during clinic visits to be able to 
pick out the impairment before they cause permanent 
damage. The patients with stable hearing impairment 
tend to deteriorate more rapidly after commencement 
of anti - retroviral therapy (1-3). 
 The goals of antiretroviral treatment are to 
improve the quality of life and reduce HIV related 
morbidity and mortality. However, this is undermined 
by the reports that some of the ARVs cause hearing 
loss thereby negating its very purpose. 
 This study was done to audiologically evaluate 
the patients who had been prescribed ARV drugs 
to establish if they were developing any significant 
hearing impairment compared to HIV infected 
patients who were not on ARVs. 
MATERIALS AND METHODS.
This was a hospital based case control study 
done between November 2006 and April 2007 at 
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ABSTRACT
Objectives: To determine if patients on Anti - retroviral drugs (ARVs) develop hearing 
impairment. 
Design: The comprehensive care clinic (CCC), Kenyatta National Hospital (KNH), 
Nairobi. 
Setting: Case controlled study. 
Subjects: Two hundred and seventy one human immunodeficiency virus (HIV) positive 
patients on ARVs were matched for age and sex with 273 HIV positive patients who 
were not on ARVs. 
Results: Thirty four percent of HIV positive patients not on ARVs had a hearing loss 
compared to only 28% in patients who were on ARVs. sensorineural hearing loss was 
the most frequent hearing disorder in both groups. Majority of the patients had mild 
hearing loss and the higher frequencies were the most affected. There was a notable 
worsening of hearing loss with increase in age, but this was not statistically significant. 
It was noted that HIV positive patients hearing level worsened on starting ARVs but 
this improved after six months of ARV treatment. 
Conclusion: Prolonged usage of ARVs is not associated with decreased hearing function. 
The most common hearing loss found in patients on ARVs is sensorineural hearing 
loss (SNHL). 
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the comprehensive care clinic, Kenyatta national 
hospital. A minimum sample size of 271 was 
required in each arm. The study subjects were HIV 
positive patients aged 18 to 50 years who had been 
on anti - retroviral drugs for at least three months 
whereas the controls were HIV positive subjects not 
on ARVs because they were new diagnosis or the 
CD4 cell counts were above 350 cells per microlitre. 
All the patients were on the 1st line ARV drugs 
namely stavudine, efavirence and lamivudine 
(5). They were matched for age and sex. Patients 
who suffered diabetes, meningitis, head injury or 
cerebrovascular accident and those who had prior 
exposure to known ototoxic medications were 
excluded from the study. Subjects who satisfied 
the criteria were consequently recruited into the 
study after written informed consent. A clinical 
history was taken followed by thorough physical 
examination, otoscopy, tuning folk tests and PTA. 
All the audiological tests were performed by the 
same person. Data analysis was done using SPSS 
10.0 software and descriptive statistics were done. 
Approval to carry out this study was obtained from 
the Ethics and Research committee of Kenyatta 
national hospital. 
RESULTS
There were 271 study patients matched for age and 
sex against 273 controls,  Figure 1 below. Most of the 
patients were in the age group 32 years to 38 years. 
 In the study group, 28% of the subjects had 
a hearing loss whereas in the control it was 34%. 
Hearing loss was more prevalent in patients who 
were not on ARVs than those who were already on 
treatment but this was not statistically significant 
(P=0.12). There was a general increase in the hearing 
loss with increasing age (Figure 2) but this was not 
statistically significant P =0.052. The hearing loss 
due to presbyacusis was not corrected since all the 
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Sensorineural hearing loss (SNHL) was the most 
common type of hearing loss in all age groups in both 
study and control groups followed by conductive 
hearing loss and a few patients had mixed type of 
hearing loss, Figure 3. In comparison, patients on 
ARVs had less CHL than those who were not on 
treatment Figure 3. 
 There was notable worsening of hearing level on 
initiation of ARVs which continued up to 6 months but 
thereafter there was a gradual improvement of hearing 
level (figure 4). However the trend improvement was 
not statistically significant (p=0.054). 
Figure 3
Types of Hearing loss along the age groups in control and study groups
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DISCUSSION
Twenty eight percent of patients on anti-retroviral 
therapy had a hearing loss of more than 25 dB in at 
least one of the hearing frequencies compared to 34% 
in the control group. Chandrasekhar et al in New York 
looked at 50 patients exposed to Zidovudine and 
Didanosine and found that 29% had a hearing loss 
(1). In this study there was no statistical difference 
in hearing loss between patients on ARVs and those 
who were not yet on ARVs (p=0.l2). However, some 
ARVs have been implicated in causing hearing loss 
(2, 6). In a prospective study done by Schouten et al, 
it was found that treatment with zidovudine and 
didanosine did not result in loss of hearing, even 
after taking into account noise exposure, immune 
status and age. The results of this prospective pilot 
study did not support the notion that treatment with 
nucleoside anti - retrovirals damages hearing (7). 
 In this study, patients who had been on ARVs 
for less than six months experienced worse hearing 
loss compared with those who had been on ARVs for 
more than six months. There was a general trend of 
worsening in the hearing level up to six months of 
treatment thereafter there was a general improvement 
in hearing level (Figure 4). This improvement in 
hearing could have been due to decrease in viral 
load and improved immunity and central nervous 
system functions at the retro-cochlear level. It can also 
be postulated that the initial hearing loss caused by 
ARV toxicity was cancelled out by the overall gains 
in improved immunity and reduced viral load. Rey 
et al reported patients who developed sensorineural 
hearing loss after exposure to ARV s, but improved 
several months later after stopping the ARVs (6). The 
control group could not be followed up to six months 
for ethical reasons as the desease progressed since 
most of them were started on ARVs.
 There was notable general increase in hearing 
loss with advancement of age though this was not 
statistically significant p> 0.05 (0.052). Marra et al also 
found an interaction between age and anti - retroviral 
therapy which was significant (p = 0.05) in subjects 
aged 35 years and above (4). It is not known if other 
aging processes are implicated or that ARVs or HIV 
cause more marked problem in the elderly, but all 
these factors have been implicated (2). 
 Majority of the patients with hearing loss had 
SNHL and this transcends across all the age groups. 
The cause of this SNHL is thought to be damage to 
mitochondrial DNA which could be due to toxicity of 
ARVs, viral toxicity or even mutations especially in the 
elderly. All these factors could synergise (3, 6, 8, 9). 
 The frequencies most affected were the higher 
levels of 4KHZ and 8KHZ. This is similar to reports 
by Chandrasekhar et al (1) and Rey et al (6), it is not 
clear why this is so, however, it is thought to be due 
to changes in cochlear mechanisms. 
 There was no significant correlation between 
hearing loss and the ARV regimes, P > 0.05 (0.42). 
This could be due to the fact that one or more 
drugs appeared in various combinations, but in a 
combination where the only difference was efavirence 
and nevirapine, no difference in hearing level was 
found. All patients were on combination therapy (5) 
hence it was difficult to know which drugs could be 
implicated as the worst in causing hearing loss. 
In conclusion, anti - retroviral therapy does not cause 
hearing loss in HIV positive patients. In the initial 
six months, the hearing loss worsens and this could 
not be explained even though it is postulated that 
this could be attributed to the ARVs ototoxicity, the 
viral disease process or due to continued middle 
ear infections until there is improved immunity due 
to the ARVs usage for more than six months when 
gradually the hearing function improves. Patients 
on ARVs should be monitored closely audiologically 
since some ARVs have been found to be associated 
with hearing loss. 
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